Arachidonic Acid

• Muscle protein synthesis
• Cellular signaling
• Immune system regulation
• Brain development

• Exercise performance
• Anabolic response to resistance training
• Cognitive function
• Skin health
• Infant development

Arachidonic acid (AA) exerts its biological effects through multiple interconnected pathways. As a structural component, AA is incorporated into cell membrane phospholipids, influencing membrane fluidity and the function of membrane-bound proteins, including receptors and ion channels. When released from cell membranes by phospholipase A2 in response to various stimuli, AA serves as the primary precursor for eicosanoid production through three major enzymatic pathways: cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP). The COX pathway produces prostaglandins (PGs) and thromboxanes, with COX-1 generating homeostatic PGs and COX-2 producing inflammatory PGs.

Particularly relevant to muscle growth, PGF2α activates the PI3K/Akt/mTOR pathway, stimulating muscle protein synthesis and hypertrophy. PGE2, another COX metabolite, has complex effects including both pro-inflammatory and anti-inflammatory actions depending on context, receptor subtype, and concentration. The LOX pathway generates leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids (HETEs), which regulate inflammatory responses and immune cell function. The CYP pathway produces epoxyeicosatrienoic acids (EETs) and hydroxyeicosatetraenoic acids, which influence vascular tone and cellular signaling.

In skeletal muscle, AA and its metabolites play crucial roles in exercise-induced adaptations. During resistance exercise, mechanical tension increases PLA2 activity, releasing AA from membranes. The resulting PGF2α production stimulates protein synthesis through mTOR activation, while PGE2 may influence protein breakdown, creating a balanced anabolic response. AA metabolites also regulate satellite cell proliferation and differentiation, essential for muscle repair and growth.

In the brain, AA is highly concentrated in neural membranes and serves as a retrograde messenger in synaptic signaling. It modulates long-term potentiation, a cellular mechanism underlying learning and memory. AA-derived endocannabinoids like 2-arachidonoylglycerol (2-AG) regulate neurotransmitter release and neuronal excitability. During early development, AA is essential for proper brain and retinal development, often working in concert with DHA.

In the immune system, AA-derived eicosanoids orchestrate inflammatory responses, with some metabolites promoting inflammation (certain prostaglandins, leukotrienes) and others resolving it (lipoxins). This dual role allows AA to both initiate necessary inflammatory responses to pathogens or tissue damage and participate in their resolution. AA also influences gene expression through direct interaction with transcription factors like PPARs and through its metabolites’ effects on various signaling pathways, including NF-κB, MAPK, and JAK/STAT, thereby regulating genes involved in inflammation, metabolism, and cellular growth.

Typical dietary intake of arachidonic acid (AA) in Western diets ranges from 100-300 mg per day. For supplementation purposes, research has primarily examined doses between 250-1500 mg daily, with most studies focusing on the 500-1000 mg range for adults.

Arachidonic acid (AA) absorption is generally efficient, with estimates ranging from 70-90% depending on the form and individual factors. As a long-chain fatty acid, AA requires bile salts and pancreatic lipase for optimal absorption in the small intestine.

Taking with a fat-containing meal increases absorption by stimulating bile release, Emulsified forms increase surface area for enhanced digestion, Phospholipid-bound AA may have superior bioavailability compared to triglyceride forms, Enteric-coated capsules protect from stomach acid degradation, Consuming with lipase-containing foods may enhance absorption, Micronized or nano-emulsified formulations increase surface area, Co-supplementation with vitamin E protects from oxidation, Consuming with lecithin or phosphatidylcholine may enhance absorption, Avoiding high doses of omega-3 fatty acids concurrently, which can compete for absorption pathways

Arachidonic acid supplements are best taken with meals, particularly those containing fat, to stimulate bile production and enhance absorption. For bodybuilders and athletes using AA to enhance training adaptations, taking the supplement approximately 30-60 minutes before resistance exercise may theoretically maximize the exercise-induced increase in prostaglandin production, though this timing strategy lacks definitive research support. Some users report dividing the daily dose, taking half in the morning and half in the evening, to maintain more consistent blood levels. For those concerned about potential sleep disruption due to AA’s involvement in inflammatory pathways, morning administration may be preferable.

When using AA specifically to support the anabolic response to resistance training, consistent daily intake throughout the training cycle (typically 4-8 weeks) appears more important than specific timing within the day. For individuals taking anti-inflammatory medications (NSAIDs), separating AA supplementation from these medications by at least 2-3 hours may be advisable to avoid direct interference with AA metabolism, though this approach is theoretical rather than evidence-based.

• Increased inflammatory markers (in some individuals)
• Gastrointestinal discomfort
• Headache
• Potential exacerbation of existing inflammatory conditions
• Increased bleeding time (theoretical at high doses)
• Skin rash or itching (rare)
• Temporary changes in blood lipid profiles
• Increased oxidative stress markers (with high doses)
• Potential sleep disturbances
• Mood changes (rare)

• Active inflammatory conditions (rheumatoid arthritis, inflammatory bowel disease, etc.)
• Cardiovascular disease
• History of stroke or thrombotic events
• Bleeding disorders
• Uncontrolled hypertension
• Peptic ulcer disease
• Asthma (particularly aspirin-sensitive asthma)
• Planned surgery within 2 weeks
• Liver disease
• Kidney disease

• Non-steroidal anti-inflammatory drugs (NSAIDs) – may alter AA metabolism and effects
• Anticoagulant medications (warfarin, heparin, etc.) – potential increased bleeding risk
• Antiplatelet drugs (aspirin, clopidogrel) – potential increased bleeding risk
• Corticosteroids – may alter inflammatory responses
• Cyclosporine – potential increased nephrotoxicity
• Omega-3 fatty acid supplements – competitive inhibition of enzymes
• COX-2 inhibitors – altered AA metabolism
• Antihypertensive medications – potential interference with blood pressure regulation
• Leukotriene modifiers (montelukast, zafirlukast) – altered AA metabolism
• 5-Lipoxygenase inhibitors – altered AA metabolism

No official upper limit has been established for arachidonic acid supplementation. Clinical studies have used doses up to 1500 mg daily for up to 8 weeks without serious adverse effects in healthy individuals. However, due to theoretical concerns regarding inflammation and cardiovascular effects, conservative approaches suggest limiting supplementation to 1000 mg daily for no more than 8-12 weeks at a time, particularly for individuals using AA for exercise performance enhancement. Long-term safety of AA supplementation has not been well-established.

For infants receiving AA in formula, the upper limit is typically set at 0.5% of total fatty acids, mimicking the upper range found in human breast milk.

In the United States, arachidonic acid (AA) is classified as a dietary ingredient under the Dietary Supplement Health and Education Act (DSHEA) of 1994 when sold as a supplement. The FDA has granted Generally Recognized as Safe (GRAS) status to specific sources of AA, particularly fungal-derived AA from Mortierella alpina, for use in infant formula and certain food applications. For infant formula, the FDA follows guidelines that recommend AA be included alongside DHA in a ratio similar to that found in human breast milk (typically between 1:1 and 2:1 AA:DHA). As a dietary supplement, AA falls under the standard regulations for supplements, which do not require pre-market approval but must comply with good manufacturing practices (GMPs) and labeling requirements.

No qualified health claims have been approved specifically for AA supplements. The FDA has not established a recommended daily intake or upper limit for AA.

Eu: The European Food Safety Authority (EFSA) has evaluated AA for use in infant formula and follow-on formula, establishing that AA should be added when DHA is added, at levels at least equal to the DHA content. The Novel Food Regulation applies to certain sources of AA, with fungal oil from Mortierella alpina approved as a novel food ingredient. AA is permitted in food supplements, though no approved health claims exist specifically for AA under EU regulations. The European Commission has established specifications for AA content in infant and follow-on formulas.

Canada: Health Canada regulates AA as a Natural Health Product (NHP) when sold as a supplement. For infant formula, Health Canada recommends the inclusion of AA when DHA is added, maintaining ratios similar to those found in human milk. Specific fungal sources of AA have been approved for use in foods and supplements. No specific health claims have been authorized for AA supplements.

Australia: The Therapeutic Goods Administration (TGA) regulates AA supplements as complementary medicines. Food Standards Australia New Zealand (FSANZ) permits the addition of AA to infant formula products, with requirements similar to international standards regarding the ratio of AA to DHA. No specific health claims have been approved for AA supplements.

Japan: The Japanese Ministry of Health, Labour and Welfare permits AA as a food ingredient and in supplements. AA is commonly added to infant formula in Japan. It is not currently approved as a Food for Specified Health Uses (FOSHU) with specific health claims.

China: The China Food and Drug Administration (CFDA) regulates AA as both a food ingredient and a health food product. Chinese infant formula standards require minimum levels of AA when DHA is added. Specific approval is required for AA sources used in infant formula and other food applications.

High to very high. Arachidonic acid (AA) supplements are among the more expensive specialty supplements on the market, particularly those formulated for bodybuilding and sports performance.

Sports performance formulations (250mg AA per serving): $1.50-3.00 per day at recommended dosage (1000mg). High-purity AA supplements (>90% purity): $3.00-5.00 per day at recommended dosage. Fungal-derived AA supplements: $2.00-4.00 per day at recommended dosage. Combined AA/DHA supplements for adults: $1.00-2.50 per day. Infant formula with added AA: Approximately $0.50-1.00 additional cost per day compared to formulas without AA.

When evaluating the cost-effectiveness of arachidonic acid supplementation, several factors should be considered beyond the simple price per milligram. For bodybuilders and strength athletes, the potential benefits on muscle protein synthesis and training adaptations may justify the relatively high cost during specific training phases, particularly when compared to the total investment in training, nutrition, and other supplements. However, the evidence base remains limited, making the value proposition somewhat speculative. The cost-benefit ratio is likely most favorable for short-term, targeted use (4-8 weeks) during intensive training periods rather than continuous supplementation.

For infant nutrition, the addition of AA alongside DHA in formula represents a well-established value, as it provides essential fatty acids critical for brain and visual development that mimic the composition of breast milk. In this context, the additional cost is generally considered justified by the developmental benefits. For general health purposes, AA supplementation offers questionable value for most individuals, as dietary sources typically provide sufficient amounts, and the potential benefits of supplementation beyond adequate dietary intake are not well-established. Additionally, concerns about promoting inflammatory pathways may outweigh potential benefits for some populations.

The source and quality of AA significantly impact both price and value. Fungal-derived AA (from Mortierella alpina) typically commands a premium price but offers higher purity and potentially fewer contaminants than animal-derived sources. For those concerned about sustainability and ethical considerations, fungal sources may provide better overall value despite higher costs. When comparing AA supplements, calculating the cost per effective dose rather than simply the cost per capsule provides a more accurate value assessment, as concentration can vary significantly between products.

Finally, considering the potential synergistic effects when combined with other supplements (for athletes) or nutrients (for infant formula) may enhance the overall value proposition beyond what AA alone might offer.

Unopened arachidonic acid (AA) supplements typically have a shelf life of 1-2 years when properly stored. Once opened, AA products should ideally be used within 2-3 months to minimize oxidation, as AA is highly susceptible to oxidative degradation due to its four double bonds.

Store in a cool, dark place away from direct sunlight and heat sources. Refrigeration is strongly recommended for all AA supplements, particularly after opening. Keep containers tightly sealed to minimize exposure to oxygen. Manufacturers typically use dark or opaque containers to protect from light exposure.

Avoid storing near appliances that generate heat. Some premium AA supplements come in individual blister packs or nitrogen-flushed containers to minimize oxygen exposure. For liquid formulations, refrigeration is essential, and some may require freezing for long-term storage. Avoid repeated freezing and thawing cycles, which can accelerate degradation.

Oxygen exposure (primary factor in oxidation/rancidity), Heat (significantly accelerates oxidation reactions), Light exposure (particularly UV light), Transition metals (iron, copper) that catalyze oxidation, Humidity and moisture, Microbial contamination (after opening), Repeated temperature fluctuations, Extended storage after opening, Exposure to strong acids or bases, Lack of adequate antioxidants in the formulation, Exposure to ozone or other oxidizing agents, Enzymatic degradation (particularly in liquid formulations)

Synthesis Methods

Natural Sources

Quality Considerations

Unlike many traditional supplements with centuries of historical use, arachidonic acid (AA) as a specific isolated compound has a relatively short history of intentional supplementation. AA was first identified and characterized in the early 20th century, with its structure determined in 1930 by the biochemist Hans Mead, leading to its alternative name ‘Mead acid’ for a related compound. Throughout most of human history, AA was consumed as a component of animal-based foods, particularly organ meats, which were highly valued in many traditional cultures. The scientific understanding of AA’s biological importance began to develop in the 1930s-1940s with research on essential fatty acids, though AA itself was not initially recognized as essential since it can be synthesized from linoleic acid in the body.

The 1960s and 1970s saw significant advances in understanding AA’s role as a precursor to prostaglandins and other eicosanoids, with the Nobel Prize-winning work of Bergström, Samuelsson, and Vane elucidating these pathways. This research initially focused on AA’s involvement in inflammation and pain, leading to the development of non-steroidal anti-inflammatory drugs (NSAIDs) that inhibit AA metabolism. The importance of AA in infant nutrition was recognized in the 1980s when researchers discovered its abundance in breast milk and its critical role in brain and visual development. This led to the addition of AA to infant formulas, often paired with DHA, beginning in the 1990s and becoming standard practice in the 2000s.

AA as a sports supplement emerged in the early 2000s, following research suggesting its potential role in muscle protein synthesis and training adaptations. The first commercial AA supplements specifically marketed to bodybuilders and strength athletes appeared around 2003-2004, with the publication of research on AA’s effects on resistance training outcomes in 2007 further popularizing its use in this context. Unlike many supplements with roots in traditional medicine, AA supplementation developed directly from scientific research without a significant history of traditional use as an isolated compound. Today, AA supplementation remains relatively niche, primarily used in specific contexts such as infant nutrition and sports performance, rather than as a general health supplement.

Jasani B, Simmer K, Patole SK, Rao SC. Long chain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database Syst Rev. 2017;3(3):CD000376., Simmer K, Patole SK, Rao SC. Long-chain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database Syst Rev. 2011;(12):CD000376., Hadley KB, Ryan AS, Forsyth S, Gautier S, Salem N Jr. The Essentiality of Arachidonic Acid in Infant Development. Nutrients. 2016;8(4):216., Tallima H, El Ridi R. Arachidonic acid: Physiological roles and potential health benefits – A review. J Adv Res. 2018;11:33-41., Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017;45(5):1105-1115.

Effects of Arachidonic Acid Supplementation on Exercise-Induced Muscle Damage and Recovery, Arachidonic Acid and Resistance Training: Effects on Muscle Protein Synthesis Signaling, Comparison of Different Omega-6:Omega-3 Ratios on Inflammatory Markers in Athletes, Long-term Safety Assessment of Arachidonic Acid Supplementation in Healthy Adults, Effects of Combined EPA and AA Supplementation on Body Composition in Resistance-Trained Individuals